Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 30, 2007BloodOpen Access

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

View Full Paper
Ask AI
Bookmark
Share

Authors

FGFrançois GuilhotInsermJAJane F. ApperleyLeiden UniversityDKDong‐Wook KimUniversity Health Network

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Guilhot et al. (2007) studied this question.

synapsesocial.com/papers/6a15a5f29b87f33fc69fbb31https://doi.org/10.1182/blood-2006-09-046839
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias2006 · 1,788 citations
  2. 2The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor.2004 · 25 citations
  3. 3Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia2002 · 310 citations
  4. 4Targeting BCR-ABL Kinase Activity-Independent Signaling Pathways and Leukemia Stem Cells Is Essential for Curative Therapy of Philadelphia Chromosome Positive (Ph+) Leukemia.2005 · 4 citations
  5. 5Active transport of imatinib into and out of cells: implications for drug resistance2004 · 640 citations